References
- Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7(1):123–133.
- Campisano F, Gramuglia F, Dawson IR, et al. gastric cancer screening in low-income countries: system design, fabrication, and analysis for an ultralow-cost endoscopy procedure. IEEE Robot Autom Mag. 2017;24(2):73–81.
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
- Ma Q, Yuan F. Pathological evaluation system for preoperative treatment of gastric cancer. Chin J Gastrointest Surg. 2018;21:1121–1124.
- Zhou ML, Zhang Z. The advantageous application value of radiotherapy in preoperative treatment of locally advanced gastric cancer. Chin J Gastrointest Surg. 2018;21:1125–1126.
- Chen J, Ye Q, Huang F. Historical evolution and research progress of perioperative therapy of locally advanced gastric cancer. Chin J Gastrointest Surg. 2019; 22:196–200.
- Kano M, Hayano K, Hayashi H, et al. Survival benefit of neoadjuvant chemotherapy with S-1 plus docetaxel for locally advanced gastric cancer: a propensity score-matched analysis. Ann Surg Oncol. 2019;26(6):1805–1813.
- Tokunaga M, Sato Y, Nakagawa M, et al. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50(1):30–37.
- Luo H, Wu L, Huang M, et al. Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: a systematic review and meta-analysis. Medicine. 2018;97(43):e12932.
- Zhou J, Shen J, Seifer BJ, et al. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget. 2017;8(18):30477–30494.
- Wang Y, Zhang J, Guo S, et al. Indications of neoadjuvant chemotherapy for locally advanced gastric cancer patients based on pre-treatment clinicalpathological and laboratory parameters. J Cancer. 2020;11(20):6000–6008.
- Paiva CE, Paiva BS. Does the Palliative Performance Scale have added value over the Karnofsky Performance Status in ambulatory cancer patients receiving palliative care? J Palliat Med. 2014;17(3):264–265.
- Vemuri RC, Jarecha R, Hwi KK, et al. Importance of volumetric measurement processes in oncology imaging trials for screening and evaluation of tumors as per response evaluation criteria in solid tumors. Asian Pac J Cancer Prev. 2014;15(5):2375–2378.
- Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch. 2018;472(2):175–186.
- Sun L. Development trend of assessment system in gastric cancer based on evolution of staging criteria. Chin J Gastrointest Surg. 2018;21:1113–1120.
- Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67(5):1025–1039.
- Zhou LY, Chen LK, Zheng XW, et al. Clinical effect evaluation of internal and external application of traditional Chinese medicine combined with intraperitoneal perfusion chemotherapy for malignant ascites in advanced gastric cancer. Chin J TCM Tech. 2019;26:256–258.
- Servarayan Murugesan C, Manickavasagam K, Chandramohan A, et al. Gastric cancer in India: epidemiology and standard of treatment. Updates Surg. 2018;70(2):233–239.
- Kanazawa Y, Yamada T, Fujita I, et al. In vitro chemosensitivity test for gastric cancer specimens predicts effectiveness of oxaliplatin and 5-fluorouracil. Anticancer Res. 2017;37(11):6401–6405.
- Migita K, Nashimoto A, Yabusaki H, et al. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. Int J Clin Oncol. 2016;21(1):102–109.
- Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017;28(8):1876–1881.
- Branca JJV, Maresca M, Morucci G, et al. Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity. Oncotarget. 2018;9(34):23426–23438.
- Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2008;39(1):2–15.
- Akune Y, Yamada M, Shigeyasu C. Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1. Jpn J Ophthalmol. 2018;62(4):432–437.
- Eckstrom J, Bartels T, Abraham I, et al. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI. Support Care Cancer. 2019;27(3):873–878.
- Wang T, Zhang SF, Qiu MQ, Li QL. Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients. Cancer Radiother. 2016;20(3):181–186.